NIMIUM Therapeutics is developing a treatment to prevent and reverse the adverse effects of excess caloric intake and to promote healthy aging 


NIMIUM Therapeutics is developing Glycerol-3-phosphate phosphatase (G3PP) activators

What is G3PP ?

G3PP activators
to counteract overnutrition

G3PP activation to promote healthy aging

Our scientists recently identified a novel enzyme that lies at the heart of glucose and lipid metabolism named glycerol 3-phosphate phosphatase. G3PP directly converts glycerol-3-phosphate, a by-product of glucose metabolism, into glycerol, thus limiting the amount of sugar available to form fat deposits and the formation of toxic reactive oxygen species (ROS). We collected multiple evidence that G3PP controls glycolysis, lipogenesis, lipolysis, fatty acid oxidation, cellular redox, and mitochondrial energy metabolism in β-cells and hepatocytes, as well as glucose-induced insulin secretion. The data indicate that G3PP is a key player in metabolic regulation and is an entirely novel target with much potential for cardiometabolic disorders.

We have shown that overexpression of G3PP in rat liver lowers hepatic glucose production from glycerol and plasma triglycerides and reduces fat deposits in hepatocytes. Furthermore, G3PP overexpression elevates plasma HDL and reduces LDL levels. NIMIUM Therapeutics is developing activators of G3PP to counteract the toxic effects of overnutrition as G3PP appears to act as a glucose excess detoxification machine.

Cardiometabolic diseases constitute a major global health challenge. These disorders also contribute to aging-related conditions and geriatric disabilities. Our research, using C. elegans, shows that enhancing G3PP activity promotes healthy aging in these animals and protects from various stresses. This is a particularly interesting avenue of research as aging is a significant risk factor for all cardiometabolic disorders and the WHO has declared 2021-2030 the Decade of Healthy Ageing.

G3PP in action

G3PP acts much like a security valve against nutrient excess. This target is a unique opportunity and an entirely novel approach towards the treatment of disorders linked to excess body weight and the prevention of associated accelerated aging.”
Dr. Marc Prentki, Director of the Montreal Diabetes Research Center and Prof at University of Montreal
Play Video

About NIMIUM Therapeutics

NIMIUM Therapeutics is a Montreal-based life-sciences start-up focused on the development of an innovative therapeutic to prevent and reverse the adverse effects of excess caloric intake and to promote healthy aging. The research is based on the discovery of glycerol-3-phosphate phosphatase (G3PP), an enzyme found to play a central role in glucose, lipid and energy metabolism in humans, which contributes to the development of cardiometabolic diseases (CMD), type 2 diabetes and obesity and other related health disorders. 

The company was founded by a team of seasoned experts in obesity and diabetes as well as in drug discovery and development. NIMIUM Therapeutics has entered into a partnership with AdMare BioInnovations, a Canadian organization that work with academia and small companies to advance preclinical research to the proof-of-concept stage, and with Paraza Pharma, a leading contract research organization with laboratories specialized in drug development. NIMIUM has also received support from the “Innovation Program” of Investissements Québec.


Philippe Walker, CEO

Philippe is one of the co-founders of NIMIUM Therapeutics, a Montreal-based life-sciences start-up focused on the development of an innovative therapeutic to prevent and reverse the adverse effects of excess caloric intake and to promote healthy aging. In 2012, he was the co-founder and CSO of the NEOMED Institute, a public-private institution designed to translate academic discoveries into high quality drug candidates. Until June 2012, Philippe was Vice-President and Head of the AstraZeneca drug discovery and development center in Montreal and member of AstraZeneca’s Global Neurosciences leadership team. In 2010, Philippe was head of Neuroscience Worldwide Drug Discovery. He has been on the Board of Directors of Arginetix and then Corridor Pharmaceuticals, representing the MediVenture Investment fund. Philippe was born and studied in Switzerland where he obtained his Ph.D. in 1986. He then joined the group of Ron Reeder at the Fred Hutchinson Cancer Center in Seattle. From 1988 to 1994, he established and directed a molecular biology research group at the Division of Hypertension of the CHUV in Lausanne Switzerland.

Marc Prentki, CSO

Marc Prentki, PhD, was trained in biochemistry at the university of Geneva.  He is currently professor of nutrition at the Université de Montréal and held a Canada Research Chair in Diabetes and Metabolism. Marc was an assistant professor working on diabetes and beta-cell function at the University of Pennsylvania and at the University of Geneva. He currently heads the Montreal Diabetes Research Center. Marc has received several awards including the young researcher award from the federation of European Endocrine Societies and the Albert Renold award from the European Association for the Study of Diabetes.

Dan Chiche, CMO

Dan Chiche MD, MSc, has a successful 20-year career history in the top tier pharmaceutical companies (Glaxo and BMS) as an executive in Clinical Research and Medical Affairs. He is a Medical Doctor with additional training in biostatistics and business administration. 
He has been involved in key clinical development of compounds in various therapeutic areas, including infectious diseases, HIV, hepatitis, influenza, hypertension, diabetes, asthma, pain, fibrosis and oncology and is fully familiarized with clinical research standards: ICH, FDA and EMA.  Dan was NEOMED’s Chief Medical Officer (CMO), a novel type of organization which pioneer an approach to bring early innovations up to phase II.  In 2007, Dan founded Kompas Medical Services Inc., a company providing services to Biotechs.

Dan is CMO at NIMIUM Therapeutics Inc.

Kemal Payza, COO

Kemal Payza earned his Ph.D. in Pharmacology and Therapeutics at the University of Florida in 1988.  He then worked on neuropeptide receptors at NIH until 1994, when he was recruited to AstraZeneca R&D in Montreal.  He established the Molecular Pharmacology Department, directed Lead Generatio, and contributed to AZ teams on Lead Optimization, Strategy, and Portfolio Management. Payza provided critical advice on project progression, managed resources, and evaluated in-licensing opportunities.  In 2012, Payza became one of the founding members of NEOMED, where he evaluated and led projects, provided pharmacology oversight, portfolio modeling and management. One of Payza’s research efforts delivered a P2X3 antagonist, BLU5937 licensed to Bellus Health, now in Ph 2.  Payza executed an HTS campaign that identified activators of the enzyme. In June 2020, he became Head of R&D at Neurasic Therapeutics, and Chief Operating Officer at Nimium Therapeutics.

Murthy Madiraju, CRO

S.R. Murthy Madiraju, is a Senior Scientist since 2005 at the Montreal Diabetes Research Center, CRCHUM, working with Dr. Marc Prentki. Murthy obtained a PhD in Biochemistry in 1982 from the Postgraduate Institute of Medical Sciences and Education, India, and moved to Montreal, to work as a postdoctoral fellow at IRCM. During his career from PDF to Research Asst Professor/ Senior Researcher at IRCM, Murthy delineated the mechanisms of fatty acid transport into mitochondria and the role of carnitine acyltransferases. He made many seminal observations in fatty acid metabolism and some of these are incorporated in text books of Biochemistry, and also made it possible to identify the cause for certain form of crib death in infants. Murthy also identified the importance of the carnitine system in transcriptional regulation. Later, Murthy joined GeminX Pharmaceuticals Montreal as Group Leader of Drug Discovery and led a team of scientists for discovering the first small molecule inhibitor (Obatoclax) of BCl2 proteins that entered clinical trials for cancer. Subsequently, working with Marc Prentki, Murthy played a significant role in the concept development and identification of ABHD6 and monoacylglycerols as important regulators of glucose and insulin homeostasis and in the discovery of mammalian G3PP. Both ABHD6 and G3PP are now being explored as potential therapeutic targets for multiple metabolic diseases. Murthy has published more than 65 peer-reviewed scientific papers and is a principal or co-investigator on research grants.


+ 1 (514) 814 3200